Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.
作者信息
Curtiss Frederic R, Fairman Kathleen A
出版信息
J Manag Care Pharm. 2010 Jan-Feb;16(1):59-66. doi: 10.18553/jmcp.2010.16.1.59.
Abstract
摘要
相似文献
1
Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.帕利珠单抗预防婴儿呼吸道合胞病毒并发症的使用管理机会。
J Manag Care Pharm. 2010 Jan-Feb;16(1):59-66. doi: 10.18553/jmcp.2010.16.1.59.
2
Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.在商业和管理式医疗补助健康计划中，与帕利珠单抗依从性相关的医疗利用情况。
J Manag Care Pharm. 2010 Jan-Feb;16(1):23-31. doi: 10.18553/jmcp.2010.16.1.23.
3
Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.在一家管理式医疗组织中，帕利珠单抗预防呼吸道合胞病毒感染的预先授权结果描述。
J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22. doi: 10.18553/jmcp.2010.16.1.15.
4
Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.对一组高危儿童进行帕利珠单抗治疗的直接成本分析：来自北卡罗来纳医疗补助计划的证据。
Pediatrics. 2004 Dec;114(6):1612-9. doi: 10.1542/peds.2004-0959.
5
A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.对帕利珠单抗用于呼吸道合胞病毒免疫预防给药依从性的系统评价。
J Manag Care Pharm. 2010 Jan-Feb;16(1):46-58. doi: 10.18553/jmcp.2010.16.1.46.
6
Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants: a note of caution.帕利珠单抗预防高危婴儿呼吸道合胞病毒感染：一则警示
J Paediatr Child Health. 2003 Nov;39(8):637. doi: 10.1046/j.1440-1754.2003.00253.x.
7
Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.呼吸道合胞病毒预防在各种适应症中的成本效益。
Arch Pediatr Adolesc Med. 2011 Jun;165(6):498-505. doi: 10.1001/archpediatrics.2010.298. Epub 2011 Feb 7.
8
Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.帕利珠单抗用于高危婴儿呼吸道合胞病毒预防：一项成本效益分析。
Clin Ther. 2000 Nov;22(11):1357-69. doi: 10.1016/s0149-2918(00)83032-5.
9
Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.德国对预防早产儿呼吸道合胞病毒相关住院治疗的可行性进行的经济学评估。
Eur J Pediatr. 2003 Apr;162(4):237-44. doi: 10.1007/s00431-002-1106-6. Epub 2003 Feb 6.
10
The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .帕利珠单抗预防胎龄 32-35 周早产儿呼吸道合胞病毒感染的成本效果分析：基于加拿大的研究
Curr Med Res Opin. 2008 Nov;24(11):3223-37. doi: 10.1185/03007990802484234. Epub 2008 Oct 16.
Zotero 插件